The quarterback of your cancer care.

Your tumor is analyzed at the DNA level to identify the specific mutations driving its growth. Unlike basic genetic panels that check a handful of genes, comprehensive profiling reads hundreds of genes at once, painting a complete molecular portrait of your cancer.

• Reveals targetable mutations your oncologist can match to approved or experimental drugs
• May identify treatments approved for a different cancer type that still apply to yours
• Flags biomarkers like TMB and MSI that predict whether immunotherapy is likely to work
• Opens doors to clinical trials that require specific mutations for enrollment

Some cancers are partly caused by mutations you were born with, passed down through families. Germline testing looks at your inherited DNA to find these variants, most commonly in genes like BRCA1, BRCA2, Lynch syndrome genes, and dozens of others depending on your cancer type.

• Identifies targeted drugs (like PARP inhibitors) that work specifically against hereditary mutations
• Tells you if family members are at elevated risk and should be screened early
• Informs a long-term surveillance strategy for second cancers in you
• Often covered by insurance when ordered for appropriate cancer types

A fresh sample of your tumor cells is kept alive and exposed to a library of cancer drugs. Instead of predicting what might work based on genetics alone, this test directly measures how your actual cancer responds, watching which drugs kill the cells and which ones don't.

• Identifies effective drugs that molecular profiling alone might miss
• Screens off-label drugs that standard guidelines wouldn't normally suggest
• Particularly valuable when your cancer is rare or has already progressed through standard treatments
• Gives your oncologist a data-backed rationale for trying non-standard options

Tumors shed tiny fragments of their DNA into your bloodstream. Liquid biopsy captures these circulating tumor DNA (ctDNA) fragments from a blood draw, with no surgery or repeat biopsy needed. Serial testing over time creates a real-time picture of how your cancer is changing.

• Detects residual disease after surgery or treatment, before it shows up on scans
• Catches early signs of recurrence weeks to months before imaging can
• Monitors whether treatment is working in real time
• Tracks new resistance mutations as they emerge, signaling when to change course

Your immune system plays a central role in fighting cancer, but tumors develop ways to hide from it or suppress it. Immune profiling examines which immune cells are present in your tumor, what targets they recognize, and whether they're active or suppressed, creating a portrait of your tumor's immune environment.

• Predicts whether checkpoint inhibitors (PD-1/PD-L1 drugs) are likely to work for you
• Identifies neoantigens, tumor-specific proteins that can be targeted by vaccines or cell therapies
• Informs whether adoptive cell therapies like TIL or CAR-T are worth exploring
• Helps personalize combination strategies that pair immunotherapy with other treatments

Standard tests analyze a tumor sample as an average of all cells mixed together. Single-cell and spatial profiling goes much further, reading the DNA and gene activity of individual cells and mapping exactly where in the tumor each cell type lives. It reveals the hidden complexity inside what looks like a single tumor.

• Uncovers rare cell subpopulations, including resistant clones, that bulk sequencing misses
• Reveals how tumor and immune cells interact spatially, key to understanding why immunotherapy works or fails
• Surfaces novel therapeutic targets not visible through conventional genomic analysis
• Increasingly used by leading academic centers for complex or treatment-resistant cases